Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04697875
Other study ID # 2020-02163_A1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date May 31, 2023

Study information

Verified date May 2022
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study hemodynamic effects of acute normobaric hypoxia during exercise in patients with pulmonary hypertension in a single-center randomized controlled trial.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 31, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent as documented by signature (Appendix Informed Consent Form) - PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure >20 mmHg, pulmonary vascular resistance =3 wood units, pulmonary arterial wedge pressure =15 mmHg during baseline measures at the diagnostic right-heart catheterization Exclusion Criteria: - resting partial pressure of oxygen <8 kilopascal at Zürich altitude on ambient air - exposure to an altitude >1000 m for =3 nights during the last 2 weeks before the study - inability to follow the procedures of the study - patients who take nitrates - other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Normobaric hypoxia (FiO2 15%)
Inhalation of deoxygenated air through an altitude simulator ("Altitrainer"), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Placebo-ambient air (FiO2 21%)
Inhalation of room air through an altitude simulator ("Altitrainer"), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.

Locations

Country Name City State
Switzerland UniversityHospital Zurich, Department of Pulmonology Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary mean pulmonary artery pressure (mPAP) / cardiac output (CO) Difference in mPAP/CO during exercise between tests under hypoxia vs. normoxia 2 hours
Secondary Differences in pulmonary arterial pressure Differences in pulmonary arterial pressure at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in cardiac output Differences in cardiac output at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Pulmonary vascular resistance Differences in pulmonary vascular resistance at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in pulmonary artery wedge pressure Differences in pulmonary artery wedge pressure at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in right atrial pressure Differences in right atrial pressure at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in mixed venous oxygen saturation Differences in mixed venous oxygen saturation at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in heart rate Differences in heart rate at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in blood pressure Differences in blood pressure at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in oxygen saturation Differences in oxygen saturation at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in arterial blood gases Differences in arterial blood gases at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in mixed venous blood gases Differences in mixed venous blood gases at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in cerebral tissue oxygenation Differences in cerebral tissue oxygenation at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in muscle tissue oxygenation Differences in muscle tissue oxygenation at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in symptoms (Borg dyspnoea) Differences in symptoms (Borg dyspnoea) at rest and during exercise, with normoxia/hypoxia 2 hours
Secondary Differences in symptoms (Borg leg effort) Differences in symptoms (Borg leg effort) at rest and during exercise, with normoxia/hypoxia 2 hours
See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Terminated NCT00384865 - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Phase 2
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting NCT02558582 - Effect of Exercise Training in Patients With Pulmonary Hypertension N/A
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Completed NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension N/A